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AbstrACt
Introduction Up to half of all women diagnosed with 
gestational diabetes mellitus develop type 2 diabetes 
within 5 years after delivery. Metformin is effective in 
preventing type 2 diabetes in high- risk non- pregnant 
individuals, but its effect when commenced in the 
postnatal period is not known. We plan to assess the 
feasibility of evaluating metformin versus placebo in 
minimising the risk of dysglycaemia including type 2 
diabetes after delivery in postnatal women with a history 
of gestational diabetes through a randomised trial.
Methods and analysis Optimising health outcomes 
with Metformin to prevent diAbetes After pregnancy 
(OMAhA) is a multicentre placebo- controlled double- 
blind randomised feasibility trial, where we will randomly 
allocate 160 postnatal women with gestational diabetes 
treated with medication to either metformin (intervention) 
or placebo (control) tablets to be taken until 1 year after 
delivery. The primary outcomes are rates of recruitment, 
randomisation, adherence and attrition. The secondary 
outcomes are maternal dysglycaemia, cost and quality of 
life outcomes in both arms, and acceptability of the study 
and intervention, which will be evaluated through a nested 
qualitative study. Feasibility outcomes will be summarised 
using descriptive statistics, point estimates and 95% CIs.
Ethics and dissemination The OMAhA study received 
ethics approval from the London- Brent Research Ethics 
Committee (18/LO/0505). Trial findings will be published 
in a peer- reviewed journal, disseminated at conferences, 
through our Patient and Public Involvement advisory group 
(Katie’s Team) and through social media platforms.
trial registration number ISRCTN20930880
IntroduCtIon
Gestational diabetes mellitus (GDM) is a 
condition with glucose intolerance first diag-
nosed in pregnancy. Up to 50% of women 
diagnosed with gestational diabetes prog-
ress to type 2 diabetes within the first 5 years 
after delivery.1 Women with gestational 
strengths and limitations of this study
 ► Double- blind randomised feasibility study on trial 
processes, glycaemic effects, cost and quality of life 
outcomes.
 ► Qualitative evaluation of the acceptability of the tri-
al and intervention to participants and healthcare 
professionals.
 ► Pragmatically designed with patient and public advi-
sory input on trial design, management and dissem-
ination of findings.
 ► Exclusion of participants with non- proficiency in 
English language as this group may include minority 
ethnic groups who are most at risk for type 2 diabe-
tes and can potentially benefit from the trial.
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Table 1 Definitions of maternal dysglycaemia using various diagnostic criteria
Variable Definition Recommending organisation
Impaired fasting glucose A fasting plasma glucose between 6.1 and 6.9 mmol/L NICE Guidance26
Impaired glucose 
tolerance
A fasting plasma glucose of <7.0 mmol/L or a 2- hour 
venous plasma glucose (after ingestion of 75 g oral 
glucose load) of 7.8–11.0 mmol/L.
WHO diagnostic criteria recommended 
by NICE26
High risk of type 2 
diabetes
A blood glucose measurement of HbA1c ((42–47 mmol/
mol) 6.0%–6.4%) or a fasting blood glucose of 5.5–
6.9 mmol/L
NICE Guidance26
Gestational diabetes A fasting plasma glucose level of 5.6 mmol/L or above or 
a 2- hour plasma glucose level of 7.8 mmol/L or above, 
after ingestion of 75 g oral glucose load
NICE Guidance9
Type 2 diabetes A fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or 2- 
hour plasma glucose ≥11.1 mmol/L in OGTT or
HbA1c>48 mmol/mol (6.4%)
WHO diagnostic criteria recommended 
by NICE Guidance26
NB: WHO- World Health Organisation, NICE- National Institute for Health and Care Excellence, HbA1c- Haemoglobin A1c.
NICE, National Institute for Health and Care Excellence; OGTT, oral glucose tolerance test.
diabetes who require pharmacological treatment are 
at an increased risk of progression to type 2 diabetes.2 
However, only a fifth of women with gestational diabetes 
undergo postnatal screening for type 2 diabetes in the 
first year, with many lost to follow- up further on.3 Undi-
agnosed type 2 diabetes increases the risks of stillbirth, 
miscarriage and congenital abnormalities in subsequent 
pregnancies.4
Metformin has been shown to be effective in reducing 
the incidence of type 2 diabetes in general populations at 
risk of the disease.5 In systematic reviews of randomised 
trials, metformin reduced the risk of developing type 2 
diabetes by up to 50% in women with a history of gesta-
tional diabetes.6 7 One of the large primary studies, the 
Diabetes Prevention Programme, demonstrated that 
the reduction in type 2 diabetes risk persisted 10 years 
after commencing metformin in women with gestational 
diabetes.5 However, none of the studies commenced the 
intervention in the postnatal period, and these involved 
mostly older women than young mothers.8
The immediate postnatal period offers a unique 
window of opportunity to intervene and prevent progres-
sion to type 2 diabetes especially in women who are at 
an increased risk of this condition and also lowering 
the risks of entering subsequent pregnancies with undi-
agnosed type 2 diabetes. Metformin intake in the post-
natal period has the potential to achieve these benefits. 
Although metformin is currently offered in pregnancy to 
treat gestational diabetes, the acceptability of continuing 
or starting the medication in the immediate postnatal 
period and taking it for a prolonged period after delivery 
is not known. Prior to a large- scale randomised placebo- 
controlled trial on the effectiveness of metformin to 
prevent type 2 diabetes after gestational diabetes, a feasi-
bility study is needed. The use of a placebo in the trial is 
needed to recognise the psychobiological effects attrib-
utable to the overall therapeutic context in the clinical 
setting.
Aims and objectives
We aim to conduct a feasibility study on the effectiveness 
of metformin in preventing dysglycaemia and progression 
to type 2 diabetes after delivery in women with gestational 
diabetes using metformin compared with placebo, and 
to assess the acceptability of the intervention and study 
procedures to women and healthcare professionals.
Primary objectives
Our primary objective is to obtain real- time data relevant 
to the trial design and trial processes such as recruitment, 
randomisation, follow- up and outcome assessment. We 
will determine the proportion of screened women who 
are eligible, the proportion recruited and randomised, 
and women’s adherence to the study protocol and inter-
vention. We will collect data on the rates of follow- up at 
6–13 weeks, 6 months and 1 year post delivery.
Secondary objectives
Our secondary objectives include assessment of accept-
ability of the trial to women, their perceptions of risk and 
benefits of metformin, barriers to adherence, and the 
dose of metformin that is acceptable to women. We will 
explore the acceptability of the trial to healthcare profes-
sionals, barriers to recruitment and adherence to study 
protocol and intervention delivery. The potential role of 
the intervention and the trial in routine clinical practice 
will also be explored. We will obtain preliminary estimates 
on the effects of metformin on dysglycaemia (pre- diabetes 
(impaired fasting glucose, impaired glucose tolerance) 
and type 2 diabetes), and weight change at 1 year after 
delivery, identify any side effects from the intake of 
metformin to mothers and their babies, and obtain rele-
vant cost data to inform future economic evaluation. 
See table 1 for the definitions of maternal dysglycaemia. 
We will determine the robustness of the randomisation 
and data collection process, healthcare professionals’ 
adherence with the study protocol in secondary and in 
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Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Women diagnosed with gestational diabetes as per the 
National Institute for Health and Care Excellence criteria, 
at time of consent and who are treated with metformin 
and/or insulin in pregnancy.
1. Women diagnosed with pre- existing type 1 or type 2 diabetes
2. Women with a body mass index of ≥50 kg/m2
3. Known contraindications to metformin
 ► Hypersensitivity to metformin hydrochloride or to any of the 
excipients.
 ► Liver failure or liver dysfunction at the time of trial entry.
 ► Renal failure or renal dysfunction at the time of trial entry.
 ► Intravascular administration of iodinated contrast agents 
planned or received within 48 hours from commencing study 
medication, (metformin can be taken only after renal function 
has been re- evaluated and found to be normal.)
2. Aged 16 years or over at the time of consent. 4. Known very severe lactose intolerance
3. Able to provide written informed consent in English 
language.
5. Women being treated with metformin postnatally, for polycystic 
ovary syndrome
6. Any acute conditions at the time of trial entry with the potential 
to alter renal function
primary care and identify the level of support required 
for successful recruitment.
MEthods
Ethical approval and study setting
The Optimising health outcomes with Metformin to 
prevent diAbetes After pregnancy (OMAhA) trial is a 
multicentre, randomised, placebo- controlled, double- 
blind, feasibility trial with a nested qualitative evalua-
tion. Ethical approval was granted by the London- Brent 
Research Ethics Committee (18/LO/0505), in May 2018. 
The OMAhA trial will be conducted at Royal London 
Hospital (RLH), Whipps Cross University Hospital 
(WXH) and Newham University Hospital (NUH) over a 
period of 20 months (November 2018–July 2020).
recruitment, randomisation and blinding
Setting
Women will be recruited from the joint obstetric diabetes 
antenatal clinic of the participating hospitals.
Eligibility
Pregnant women diagnosed with gestational diabetes and 
on treatment with either metformin or insulin or both and 
fulfil the criteria in table 2 are eligible for recruitment.
Screening and consent
Potentially eligible participants will be screened to 
confirm eligibility prior to being approached by a 
member of the research team during their antenatal visit 
to the joint obstetric diabetes clinic. A record of women 
who are screened, but not eligible, and eligible women 
who do not provide consent will be kept in the screening 
log. Anonymised information on these participants will 
include age, ethnicity and reasons for being ineligible or 
declining consent.
Eligible participants will receive the patient informa-
tion sheet (PIS) prior to their hospital booking visit. A 
researcher will approach the eligible woman and review 
the PIS and answer any questions. We will obtain written 
informed consent to participate in the quantitative part 
of the study. A small proportion of participants will 
also be asked to provide written informed consent for 
the qualitative part of the study. In cases where women 
have been approached during their antenatal visits, but 
had not given consent yet, they may be consented post 
delivery but before discharge. We will collect baseline 
information on demographics and clinical characteristics 
after obtaining consent. The validated European Quality 
of life 5- Dimensions 5- Level scale (EQ- 5D- 5L) question-
naire will be administered to capture quality- adjusted life 
years (QALYs) in all participants.
Randomisation
Prior to postnatal discharge, recruited participants will 
be asked to confirm their willingness to continue with 
the trial. Once consent is obtained, participants will 
be randomised using an online randomisation system 
(epiGenesys, University of Sheffield), and allocated to 
either the active (metformin) or placebo treatment. We 
will adopt a randomisation scheme (allocation ratio 1:1) 
based on permuted blocks of random block size (sizes 4, 
6 and 8), stratified by participating site (RLH, WXH or 
NUH) with no minimisation or adaptive strategies.
Blinding
The treatment allocation lists will be created by an inde-
pendent statistician, allowing all members of the research 
team, research midwives, site staff, investigators, pharma-
cists, as well as women to remain blinded. Sharp Clinical 
Services MIA (investigational medicinal product) 10284 
will undertake the final packaging and labelling of the 
medicinal products, to further ensure complete blinding 
 on M
ay 26, 2020 at B
V
A
. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-036198 on 17 M
ay 2020. D
ow
nloaded from
 
4 Amaefule CE, et al. BMJ Open 2020;10:e036198. doi:10.1136/bmjopen-2019-036198
Open access 
to all, apart from the independent statistician. The online 
randomisation system will also provide the unblinding 
service if required. The study code will only be broken 
for valid medical or safety reasons such as severe adverse 
events (SAEs), or in the event of a patient being diag-
nosed with type 2 diabetes during the course of the study 
and if they or their general practitioner (GP) request this 
information in order to determine further management.
Intervention and control arms
Participants will be provided with either placebo or 
metformin sustained- release 500 mg tablets after child-
birth, prior to postnatal discharge. Participants will be 
advised to commence the trial medication from discharge 
until 12 months post delivery, to achieve a target dose 
regimen of 2 g/day. The placebo is identical in appear-
ance, smell and taste to the metformin tablets. For 
metformin- naïve participants, the study tablets will be 
titrated in increments of 500 mg to reduce gastrointes-
tinal side effects. The titrating dosing schedule will be: 
1 g daily in week 1, 1.5 g daily in week 2 and 2 g daily in 
week 3 until the end of the study. For women continuing 
metformin, they will be titrated to the target dose in a 
similar way. All trial participants will be contacted by the 
research midwives to increase the dose of their trial medi-
cation accordingly. The target dose can be taken as four 
500 mg tablets with a meal one time a day or two tablets 
two times per day with meals. Dosage will be adjusted 
based on participant tolerance to side effects, adverse 
events (AEs) and if women request to have at least 1 g/
day.
As part of routine clinical practice and independent of 
the trial, women may receive advice, guidance and inter-
ventions in line with the NICE guideline on preventing 
type 2 diabetes.9
outcomes
Primary outcomes
Primary outcomes include process evaluation outcomes 
such as the proportion of screened women who are 
eligible; the proportion of eligible women who are 
recruited; the proportion of recruited women who are 
randomised; attrition rates and adherence rates with the 
intervention.
Secondary outcomes
 ► Acceptability outcomes such as women’s views of the 
recruitment process; risk of type 2 diabetes and bene-
fits of metformin;factors that influence their decision 
to participate and adhere to the intervention and the 
optimum dose of metformin acceptable to mothers 
postnatally. Additionally, healthcare professionals’ 
experience on approaches to prevent type 2 diabetes 
after gestational diabetes including their views on the 
barriers to recruitment, adherence and retention.
 ► Clinical outcomes such as maternal dysglycaemia 
(prediabetes (impaired fasting glucose, impaired 
glucose tolerance) and type 2 diabetes, see table 1 for 
definitions) at 6–13 weeks and 1 year after delivery; 
fasting and 2- hour glucose post 75 g glucose load, 
insulin levels, HbA1c levels and Homeostasis Model 
Assessment of Insulin Resistance (HOMA- IR) at 6–13 
weeks, and 1 year; HbA1c levels and proportion of 
women with type 2 diabetes at 6 months after delivery; 
maternal weight gain at 6 months, and 1 year after 
delivery; breast feeding at 3 months, 6 months and 
1 year; and side effects of metformin in mothers and 
their babies.
 ► Economic outcomes such as EQ- 5D- 5L, health and 
social care resource use and costs.
 ► Study conduct related outcomes such as the frequency 
and nature of protocol deviations, randomisation 
issues, data queries and monitoring findings for 
dispensing medication; and specific requests from 
health professionals for support to ensure successful 
recruitment.
Participant follow-up
Follow-up visits and outcome assessment
Randomised participants will be followed up at three 
study visits: 6–13 weeks, 6 months and 1 year post delivery. 
Participant follow- up will be conducted primarily in 
person or by phone based on availability. Within a week 
post discharge, participants will be contacted by the 
research midwives to ensure or encourage the immediate 
commencement of the trial medication. Between visits, 
participants will be contacted monthly by phone to review 
progress, document any side effects, encourage adher-
ence and remind participants to discontinue their study 
medication for 1 week prior to their next follow- up visit. 
To encourage adherence, participants will be offered 
an optional mobile Application (Dosecast)10 with daily 
automated reminders to take the intervention. Partici-
pants will also receive short motivational updates every 
2–3 months by text or email, about study progress, with 
the aim of promoting ongoing engagement with the 
study. At each follow- up visit, maternal and baby outcomes 
will be collected, along with whole blood samples. An oral 
glucose tolerance test will be performed at the 6–13- week 
and 1- year visits in accordance with standard NHS labo-
ratory practice and logged onto a secure NHS database. 
HbA1c will be tested at all three follow- up visits to diag-
nose type 2 diabetes. Non- routine tests, fasting insulin 
and c- peptide will be carried out by Affinity Biomarker 
Labs (Imperial College London, W12 0BZ). HOMA- IR 
will be calculated from the fasting glucose and fasting 
insulin levels.11 Maternal and baby outcomes will also be 
collected as outlined in figure 1.
Participants will self- report adherence by using a paper- 
based diary or mobile app10 depending on their pref-
erence. Participants will also be asked to bring in their 
unused medication bottles for tablet counting. Partici-
pants who successfully complete their research visits will 
be reimbursed with a £10 shopping voucher for their 
efforts, at each of the three follow- up visits.
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Figure 1 Flow chart of the Optimising health outcomes with Metformin to prevent diAbetes After pregnancy feasibility trial. 
BMI, body mass index; GDM, gestational diabetes mellitus; HOMO- IR, Homeostasis Model Assessment of Insulin Resistance; 
OGTT, oral glucose tolerance test.
Withdrawal criteria
Withdrawal of consent will be respected and recorded 
on the final study form, and the participant will continue 
with NHS standard practice for follow- up care. A partic-
ipant can also be withdrawn by her clinical team or 
the trial investigators if it is considered to be medically 
necessary. Where possible, the withdrawn participant 
will be followed up for all safety and efficacy outcomes. 
Following testing for type 2 diabetes, women found to 
have pre- diabetes will stay on the trial. Women diagnosed 
with type 2 diabetes will be withdrawn from the trial and 
transferred to primary care for further treatment. In this 
event, if women provide consent, their GP will be notified 
of their diagnosis. On request, the GP will be notified of 
their treatment allocation to inform further treatment 
decision.
sample size
We expect that at least 1000 women diagnosed with 
gestational diabetes annually are eligible for participa-
tion. We anticipate one- third of these women to consent 
and be randomised to the study, resulting in 160 women 
randomised over 6 months. With an attrition rate of 20%, 
we expect 128 of the 160 women to remain in the trial 
and 80% (102/128) to be followed up. These numbers 
will allow for the estimation of 95% CIs for trial feasibility 
outcomes with amplitudes of around 10% in the worst 
case of p=q=0.5.
Qualitative evaluation
Recruitment observation
After obtaining verbal consent from eligible women 
being approached, a qualitative researcher will observe 
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the recruitment process in a sample of participants at 
each site to gain detailed knowledge of women’s needs 
and concerns during recruitment, as well as factors within 
the recruitment setting that may influence participation.
Semistructured interviews
Following consent, a purposive sample of 10–15 women 
will be interviewed around the 6–13- week visit, and 
5–8 women near their 12 months visit. The main goal 
of purposive sampling is to ensure variation in partic-
ular characteristics of the population under study that 
may influence their response towards the intervention 
(eg, previous diagnosis of GDM, parity, ethnicity). The 
first set of interviews at 6–13 weeks post discharge will 
explore participants’ views of the recruitment process, 
understanding of type 2 diabetes, their perception of 
risk of developing type 2 diabetes, reasons for participa-
tion, perceived acceptability of metformin, the adher-
ence tools and possible reasons for non- adherence. 
The second set of interviews will focus on participants 
who found adherence particularly easy or difficult, and 
explore perceptions of follow- up procedures and adher-
ence to the intervention. Concepts identified from the 
first set of interviews will inform discussions in the second 
interviews. Alongside this, we will endeavour to interview 
a sample of women who drop out of the trial. Interviewees 
will receive a £10 voucher for their time.
Approximately, 10 healthcare professionals who are 
involved in the intervention delivery or care of women 
with postnatal type 2 diabetes will be interviewed. This may 
include research midwives, diabetes specialist midwives, 
trial coordinators, GPs and diabetologists. We will explore 
experiences of intervention delivery, potential role of the 
intervention in routine practice and perceived barriers 
and support required for its implementation in practice.
Qualitative interview data will be analysed themat-
ically using constant comparison techniques, to iden-
tify and interpret patterns (themes) within the data, 
which represent beliefs and experiences that partici-
pants share (or differ on) in relation to the research 
questions. Transcripts will be coded for themes and 
subthemes in relation to the trial experiences of women 
and healthcare professionals. We will develop an analyt-
ical framework to capture inter- relationships between 
themes.
statistical analysis
Data will be analysed using descriptive statistics to 
inform trial feasibility and process. We cannot reliably 
assess the effect of the intervention on outcomes, given 
the size of this feasibility study and hence hypothesis 
testing is not proposed. We will summarise feasibility 
outcomes using standard methods for proportions and 
other descriptive statistics, and where appropriate, we 
will present point estimates of proportions, and effect 
sizes (eg, mean differences and relative risks) with asso-
ciated 95% CIs.
Economic evaluation
The cost–utility analysis of metformin versus placebo 
will involve using a short- term time horizon (the ‘within 
trial’ period), which will inform the definitive trial. The 
cost–utility measures will be the incremental cost per unit 
of change per QALY gained. The costs to women in the 
intervention and control group will be assessed from the 
perspectives of the NHS, personal and social services. Cost 
components include the cost of metformin and placebo 
including their administration, cost of routine tests, labo-
ratory tests and further investigations, costs of clinic visits, 
hospital admissions (length of stay), antenatal costs, post-
natal costs, neonatal costs and costs to treat AEs. Resource 
use data will be prospectively collected at patient level 
using clinical records and diaries. Unit costs will be taken 
from standard sources. Quality of life outcomes will be 
assessed from data collected using a validated question-
naire. Data on health- related quality of life collected using 
the EQ- 5D- 5L questionnaire will inform the QALYs calcu-
lation. The QALYs experienced from baseline to end of 
trial will be calculated as the area underneath this profile. 
Cost–utility will be calculated as the mean cost difference 
between the intervention and control group divided by 
the mean difference in outcomes to give the incremental 
cost- effectiveness ratio.
Pharmacovigilance and safety
Any untoward medical occurrence in a participating 
woman which may or may not be related to or caused by 
the medicinal product is an AE. Any untoward medical 
occurrence in a participating woman that is life threat-
ening results in death, requires inpatient hospitalisation 
or prolongation of existing hospitalisation, results in 
persistent or significant disability/incapacity is a SAE. All 
serious SAEs and suspected unexpected serious adverse 
reaction will be reported to the sponsor and medicinal 
product provider (as per supply agreement) within 
24 hours of the chief investigator or local investigators 
becoming aware of the event.
trial oversight, monitoring and data management
The trial will be overseen monthly by a trial management 
group (TMG) at the Barts Research Centre for Women’s 
Health at Queen Mary University of London. The trial 
will also be overseen by two independent groups, the 
trial steering committee (TSC) and the data monitoring 
committee (DMC) ensuring that the trial is conducted 
according to the principles of Good Clinical Practice in 
Clinical Trials.
The OMAhA study will be monitored via on- site moni-
toring using a trial monitoring plan. Any serious breach 
that significantly affects the safety, physical or mental 
integrity of the participants or the scientific value of the 
trial will be made known to the sponsor within 24 hours. 
The research team at Barts Health NHS Trust will have 
access to participants’ personal data for consent, data 
entry into case report forms and follow- up. However, 
all participant data will be pseudoanonymised using a 
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unique identifier before use. All participant data will be 
held securely and treated as strictly confidential.
Progression criteria
To randomise 160 women over 8.5 months, we will need to 
recruit 200 women at Barts Health NHS Trust. An average 
monthly recruitment rate of 15 women or more, adher-
ence rates of ≥75% or more to the study intervention 
(high adherence) and a follow- up of 80% or more will 
be clear indicators of progression to a full- scale trial. An 
average recruitment rate of five women or less monthly, 
adherence <50% and follow- up <50% will require a full 
re- evaluation of trial processes taking into account the 
qualitative findings prior to progression to a full- scale 
trial. Any estimates between the two criteria aforemen-
tioned will trigger a re- evaluation of trial procedures with 
minimal to moderate changes to improve outcomes.
Participant and public involvement and dissemination
Participant and public involvement
Katie’s Team, a women’s health specific patient and 
public involvement advisory group12 13 has codeveloped 
the OMAhA study protocol by providing input into the 
design (reviewing and refining the protocol, participant- 
facing documents and input into the qualitative interview 
schedule). As members of the TSC, they will assess study 
conduct.
Dissemination
Findings from the OMAhA study will be published in a 
peer- reviewed journal and disseminated through confer-
ence presentations with input from Katie’s Team, and the 
findings will be circulated to participants as fact sheets. 
We will also disseminate the findings to our local commu-
nity groups and other relevant stakeholders through the 
Maternity Service Liaison Committees and social media 
platforms.
dIsCussIon
The OMAhA trial is a crucial step towards global efforts 
to reduce the burden of type 2 diabetes by targeting high- 
risk women with gestational diabetes. Until now, it is not 
known if metformin, a drug that prevents type 2 diabetes 
in the general population at risk, is also effective in post-
natal period to prevent the disease after a history of gesta-
tional diabetes.8 Our feasibility study is conducted in inner 
city multiethnic populations of young women within an 
NHS setting, who are at highest risk of developing both 
gestational diabetes and type 2 diabetes. The effectiveness 
and acceptability of metformin in new mothers are not 
known necessitating the need for a trial in this area.
Metformin is an oral hypoglycaemic agent which has 
been used for over 60 years as an effective oral glucose 
lowering agent for type 2 diabetes. The use of metformin 
in gestational diabetes is recommended by NICE for 
treatment of gestational and type 2 diabetes.9 Metformin 
is excreted into human breast milk and to date no 
adverse effects have been observed in breastfed infants,14 
and is the recommended drug for treatment of type 2 
diabetes in postnatal mothers.9 It is available as either 
immediate release tablets or sustained- release tablets 
taken orally, both of which are approved for the treat-
ment of non- diabetic patients at high risk of developing 
type 2 diabetes.15 Maximum plasma metformin concen-
trations are reached more slowly with the sustained- 
release formulation compared with immediate- release 
metformin.16 In the OMAhA trial, we will be using the 
sustained- release formulation which allows us to imple-
ment a simpler dosing regimen, with increased tolera-
bility thus improving patient adherence and greater 
glycaemic control.
The OMAhA study’s research question was prioritised 
by our Patient and Public Involvement (PPI) Group, the 
Katie’s Team, comprising women and families with lived 
experiences of gestational diabetes. In our work leading 
to the proposal, we surveyed mothers with gestational 
diabetes, and healthcare professionals on intervention 
strategies for preventing progression to type 2 diabetes 
in women developing gestational diabetes. Our survey of 
106 healthcare professionals showed that 80% (17/21) 
of midwives and about 50% (11/21) of the obstetricians 
were unsure of the future risk of type 2 diabetes after 
gestational diabetes.17 This further hinders provision of 
interventions to prevent type 2 diabetes in the postnatal 
period. Three- quarters of mothers (50/67) were inter-
ested in continuing metformin after delivery to prevent 
type 2 diabetes. Two- thirds (52/77) of healthcare profes-
sionals said that they would offer metformin as part of 
a trial if available.18 Our meta- analyses of women with 
gestational diabetes identified women with high glucose 
levels, and those who needed insulin in pregnancy to be 
at high risk of progression to type 2 diabetes,2 and hence 
our target population includes women with gestational 
diabetes on medication.
A full- scale definitive trial on the effectiveness of 
metformin in preventing type 2 diabetes in postnatal 
women will require a large sample size and resources.19 
Randomisation, follow- up and adherence assessment 
can be challenging especially in the immediate postnatal 
period with new mothers. The physical and emotional 
tiredness of caring for a newborn, as well as the personal 
and family adjustment required can hamper adherence 
and visit attendance.20 Adverse delivery outcomes that 
may extend postnatally such as postcaesarean compli-
cations may hamper commencement of the trial medi-
cation in the early postnatal period.21 Concerns with 
metformin use while breast feeding, acceptability of the 
drug regimen and duration are possible barriers to study 
and intervention adherence. A feasibility study is vital to 
assess these study process related outcomes to inform the 
definitive trial avoiding unnecessary attrition and poor 
adherence, allowing for savings in costs, time and other 
resources. The qualitative component of the OMAhA 
study aims to explore the impact of these barriers, ascer-
tain the actual rates of follow- up, adherence and attrition, 
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identify support strategies and alternative solutions prior 
to a large- scale trial.
By recruiting participants from the joint obstetric 
diabetes clinic, we will be able to engage with the women 
who are already on metformin. Providing information 
on their subsequent risk of type 2 diabetes is expected 
to increase their motivation to join the study and adhere 
to the protocol.22 Our qualitative evaluation will assess 
the recruitment process on women’s concerns, motiva-
tions as well as contextual factors which may optimise 
or undermine research participation. By exploring the 
randomisation rates which are assessed after delivery, 
our study will determine if the experience of childbirth 
impacted on women’s willingness to continue with the 
trial.
The feasibility of collecting the required clinical 
outcome data also needs to be assessed, given the low 
uptake of postnatal screening for type 2 diabetes espe-
cially at 6–13 weeks after birth.23 The OMAhA study 
includes features to encourage visit attendance and reten-
tion in the study such as regular communication with 
women through phone calls and texts, and reminders 
of upcoming appointments. We also provide dedicated 
research staff to collect blood samples for outcomes to 
minimise the waiting times, and encourage visit atten-
dance, and also reimburse women for their time through 
vouchers. To encourage adherence, participants are 
offered an optional mobile application with daily auto-
mated reminders to take the intervention. By regular 
contact with participants, we aim to foster engagement 
with the study, and in doing so, reinforce the potential 
benefits of the intervention and study, advising on ways to 
overcome potential challenges or side effects of the inter-
vention, encouraging adherence.
Our qualitative evaluation will explore the influence 
of these support strategies on adherence, visit atten-
dance and retention, as well as eliciting suggestions from 
mothers and healthcare professionals on ways to best 
help with associated challenges. All of these learnings will 
inform the design and conduct of the full- scale definitive 
trial. As well as a nested qualitative evaluation, we have 
PPI input on the methodology and design to enhance 
acceptability and integration into routine practice.24 The 
iterative process of trial monitoring and progress review 
by the TMG and an independent team of clinical special-
ists and patient representatives (TSC and DMC) will aid 
in resolving any challenges in study conduct, in addition 
to ensuring the safety of the trial.25
Our findings on feasibility and process outcomes will 
guide our decision to progress to a full- scale trial. Our 
progression criteria are arbitrary, and we will combine 
these with qualitative insights on solutions to factors 
which may have undermined recruitment, follow- up and 
adherence, in addition to recommendations from the 
TSC.25
ConClusIon
The OMAhA study findings will inform the conduct of 
a full- scale definitive trial on the effects of metformin 
in reducing the risk of dysglycaemia including type 2 
diabetes after delivery in women with a history of gesta-
tional diabetes.
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